biostudies-literatureUnknown22(1)de la Rocha C<h4>Background</h4>Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.<h4>Methods</h4>A randomiBMC infectious diseases917https://www.ebi.ac.uk/biostudies/studies/S-EPMC9730611biostudies-literatureIvermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.PMC9730611de la Rocha CRobles-Bojorquez JGMercado-Sesma ARVargas-Iniguez BValderrabano-Roldan CGTavares-Valdez AGomez-Mendez SCGutierrez-Dieck GARosales-Galvan DLuna-Gudino NMilenkovic JMendez-Del Villar MHernandez-Puente CVIglesias-Palomares CVenegas-Lopez BICid-Lopez MASanchez-Ortiz AMercado-Cerda JLlamas-Velazquez RAPerez-Rios AMMeza-Acuna AIfalseIvermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.<h4>Background</h4>Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.<h4>Methods</h4>A randomi2022-01-01T00:00:00Z2022 Dec2026-07-14T15:22:44.395Z2024-11-08T13:29:02.531ZS-EPMC97306113648232610.1186/s12879-022-07890-6